GTF2IRD1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product achieves targeted disruption of the GTF2IRD1 gene, establishing a versatile loss-of-function model for investigating the transcriptional regulatory functions of GTF2IRD1 within a cancer cell context. The polyclonal format preserves population-level heterogeneity while eliminating wild-type GTF2IRD1 expression, enabling robust functional studies without the limitations of single-clone artifacts. Researchers can employ this model to dissect GTF2IRD1-dependent gene regulatory networks and assess its role in cellular processes relevant to both normal development and disease.
The host A-549 cell line was originally established from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and has since become a widely accepted model for alveolar epithelial biology and non-small cell lung cancer. These adherent epithelial cells retain key signaling pathways and differentiation markers characteristic of the lung adenocarcinoma phenotype, making them a tractable system for studying oncogenic mechanisms. The A-549 background provides a clinically relevant platform to examine how perturbation of developmentally important transcription factors, such as GTF2IRD1, influences cancer cell behavior, including proliferation, migration, and response to therapeutic agents.
GTF2IRD1 encodes a transcription factor located within the Williams-Beuren syndrome critical region on chromosome 7, where it functions as a key regulator of craniofacial and neural development. GTF2IRD1 operates within transcriptional regulatory networks by interacting with USF1 and the TFII-I family of proteins, including GTF2I. Mechanistically, GTF2IRD1 forms complexes with USF1 to modulate the expression of downstream target genes involved in neural crest differentiation and other developmental processes. Upstream, USF1 itself acts as a transcriptional regulator that can influence GTF2IRD1 activity, while GTF2IRD1 reciprocally mediates transcriptional responses that impact USF1-mediated programs. This crosstalk positions GTF2IRD1 at a nodal point for integrating signals that govern both developmental and pathological gene expression.
In the A-549 lung adenocarcinoma context, GTF2IRD1 knockout cells offer a unique opportunity to explore how loss of this transcription factor rewires gene expression programs that may contribute to cancer progression. Although GTF2IRD1 is best known for its developmental roles, its expression in epithelial cells and potential involvement in USF1-mediated transcriptional regulation suggest that it may modulate pathways relevant to tumor cell proliferation, survival, or differentiation. This model enables the systematic interrogation of GTF2IRD1-dependent transcriptional changes and their functional consequences in lung cancer cells, providing insights that bridge developmental biology and oncology.
Key applications include functional genomics screens to identify GTF2IRD1 target genes via RNA-seq and ChIP-qPCR, validation of protein-level knock-out by western blotting and immunofluorescence, and phenotypic characterization using cell proliferation, migration/invasion, and apoptosis assays. Additionally, these cells support disease modeling of Williams-Beuren syndrome and autism spectrum disorders by allowing researchers to reconstitute mutant contexts and assess neurodevelopmental gene expression signatures. The polyclonal knockout pool is particularly suited for high-throughput functional assays and drug discovery campaigns where population-level responses better reflect clinical heterogeneity. For further information, contact Ascent Research.
